Literature DB >> 6692296

Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment.

J P Massin, J C Savoie, H Garnier, G Guiraudon, F A Leger, F Bacourt.   

Abstract

Fifty-eight cases of pulmonary metastases (PM) from 831 cases of differentiated thyroid carcinoma (DTC) were studied. PM were found in about 10% of follicular and 5% of papillary tumors. 131I uptake was found in 55% of the cases, irrespective of histology. Twenty-one patients were treated by 131I only and 12 were cured. Micronodular metastases, 92% papillary, with 86% positive 131I uptake and 77% 8-year survival rate, are the most favorable forms. In others the influence of PM size/age, uptake, delay of appearance, presence of cervical or mediastinal lymph nodes is discussed. Occurrence of late PM according to treatment of the primary tumor was 1.3% thyroidectomy + 131I; 3% thyroidectomy; 5% partial thyroidectomy + 131I; 11% partial thyroidectomy only. Thus prevention in DTC of severe PM (28% 8-year survival rate) can best be achieved by complete thyroidectomy + 131I ablation dose.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692296     DOI: 10.1002/1097-0142(19840215)53:4<982::aid-cncr2820530427>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat, when not to treat?

Authors:  C Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07       Impact factor: 9.236

Review 2.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

Review 3.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

4.  Histochemical demonstration of thyroxine, triiodothyronine, and thyroglobulin in the primary lesion of thyroid carcinoma, and its predictability for radioiodine uptake by metastatic lesions.

Authors:  T Kodama; Y Fujimoto; T Obara; Y Ito; K Kusakabe; A Hirayama
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

5.  Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation.

Authors:  R Parameswaran; J Shulin Hu; N Min En; W B Tan; N K Yuan
Journal:  Ann R Coll Surg Engl       Date:  2016-09-23       Impact factor: 1.891

Review 6.  Recurrent thyroid cancer.

Authors:  O H Clark
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

7.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

8.  Follicular thyroid carcinoma invades venous rather than lymphatic vessels.

Authors:  Xiaoqi Lin; Bing Zhu; Yulin Liu; Jan F Silverman
Journal:  Diagn Pathol       Date:  2010-01-22       Impact factor: 2.644

9.  Utility of Iodine-131 hybrid SPECT-CT fusion imaging before high-dose radioiodine therapy in papillary thyroid carcinoma.

Authors:  Anish Bhattacharya; Sunil Hejjaji Venkataramarao; Chandra Sekhar Bal; Bhagwant Rai Mittal
Journal:  Indian J Nucl Med       Date:  2010-01

10.  Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine?

Authors:  C A Proye; D H Dromer; B M Carnaille; A J Gontier; A Goropoulos; P Carpentier; J Lefebvre; M Decoulx; J L Wemeau; P Fossati
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.